Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sleep study

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,053 result(s) found for: Sleep study. Displaying page 20 of 53.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    EudraCT Number: 2022-003452-14 Sponsor Protocol Number: SBC007C401 Start Date*: 2023-05-02
    Sponsor Name:Berlin Cures GmbH
    Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability...
    Medical condition: long Covid
    Disease: Version SOC Term Classification Code Term Level
    25.1 10021881 - Infections and infestations 10087832 COVID-19 rebound LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002138-13 Sponsor Protocol Number: GWSP0702 Start Date*: 2007-09-13
    Sponsor Name:GW Pharma Ltd.
    Full Title: A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).
    Medical condition: Symptoms of spasticity in multiple sclerosis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013789-17 Sponsor Protocol Number: CL3-20098-071 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000443-28 Sponsor Protocol Number: C3291035 Start Date*: 2020-03-27
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole Ointment, 2%, Once Daily Over 52 Week...
    Medical condition: Mild-to-Moderate Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003640 Atopic dermatitis and related conditions LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005872-41 Sponsor Protocol Number: QTZ-EC-0004 Start Date*: 2012-04-25
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study
    Medical condition: Patients who have a documented diagnosis of probable or definite Peripheral Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) FI (Completed) AT (Completed) SK (Completed) ES (Completed) BE (Completed) SI (Completed) GB (Completed) DE (Completed) GR (Completed) PT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-022955-43 Sponsor Protocol Number: A0081256 Start Date*: 2011-05-17
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
    Full Title: OPEN LABEL EUROPEAN STUDY TO SUPPORT THE EARLY IDENTIFICATION OF PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN IN PRIMARY CARE AND TO ASSESS THE EFFECTIVENESS AND TOLERABILITY OF PREGABALIN IN TH...
    Medical condition: Pregabalin (Lyrica ®) is approved in the European Union for the treatment of peripheral and central neuropathic pain in adults. The medical condition being investigated in this study is chronic neu...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005261-69 Sponsor Protocol Number: GA1402 Start Date*: 2015-08-06
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A multi-centre, randomised, double-blind, two arm, parallel group, placebo-controlled study to assess the effect of Sodium Alginate Chewable Tablets on symptoms of gastro-oesophageal reflux disease.
    Medical condition: Gastro-Oesophageal Reflux Disease (GORD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002531-32 Sponsor Protocol Number: GWCL0405 Start Date*: 2005-07-28
    Sponsor Name:GW Pharma Ltd
    Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex, in the treatment of subjects with peripheral neuropathic pain associated with allodynia
    Medical condition: Peripheral neuropathic pain associated with allodynia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022905-17 Sponsor Protocol Number: GWCA1103 Start Date*: 2011-12-26
    Sponsor Name:GW Pharma Ltd.
    Full Title: A two-part, placebo-controlled, study of the safety and efficacy of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patien...
    Medical condition: Pain in patients with advanced cancer who have inadequate analgesia even with optimized chronic opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) GB (Completed) LT (Completed) PL (Completed) DE (Completed) HU (Completed) RO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-003655-20 Sponsor Protocol Number: GWPHN0602 Start Date*: 2008-11-21
    Sponsor Name:GW Pharma Ltd
    Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of post-herpetic neuralgia.
    Medical condition: Post-herpetic neuralgia symptom relief.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005263-29 Sponsor Protocol Number: 25-01 Start Date*: 2006-01-31
    Sponsor Name:Gesellschaft fuer klinische Forschung e.V. (Society for Clinical Research) [...]
    1. Gesellschaft fuer klinische Forschung e.V. (Society for Clinical Research)
    2. WELEDA AG
    Full Title: Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sa...
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000995-24 Sponsor Protocol Number: GWEP1332 Start Date*: 2014-09-09
    Sponsor Name:GW Research Ltd
    Full Title: A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young ...
    Medical condition: Dravet Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006907-35 Sponsor Protocol Number: SP915 Start Date*: Information not available in EudraCT
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTI...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) HU (Completed) IT (Completed) GB (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000877-35 Sponsor Protocol Number: BB-2001-201b Start Date*: 2017-08-09
    Sponsor Name:BenevolentAI Bio
    Full Title: Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson’s Disease (PD).
    Medical condition: Excessive daytime sleepiness with Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002473-31 Sponsor Protocol Number: SCO/BIA-2093-207 Start Date*: 2007-10-12
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS THERAPY FOR PATIENTS WITH POST-HERPETIC NEURALGIA: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC...
    Medical condition: adult patients with post-herpetic neuralgia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036376 Post herpetic neuralgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) LT (Completed) AT (Completed) CZ (Completed) FR (Completed) HU (Completed) DE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-004364-66 Sponsor Protocol Number: BMR111-208 Start Date*: 2019-10-22
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia
    Medical condition: Achondroplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000452 Achondroplasia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004294-13 Sponsor Protocol Number: RD.06.SPR.202699 Start Date*: 2020-10-05
    Sponsor Name:Galderma S.A.
    Full Title: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005879-16 Sponsor Protocol Number: GRC17536-201 Start Date*: 2012-06-11
    Sponsor Name:Glenmark Pharmaceuticals SA
    Full Title: A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic N...
    Medical condition: Pain associated with diabetic peripheral neuropathy (DPN).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012683 Diabetic peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005372-32 Sponsor Protocol Number: ROR104836 Start Date*: 2006-02-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound...
    Medical condition: Restless Legs Syndrome (RLS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) DK (Completed) PT (Completed) CZ (Completed) HU (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002954-21 Sponsor Protocol Number: QBGJ398-201 Start Date*: 2020-05-06
    Sponsor Name:QED Therapeutics, Inc.
    Full Title: Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2
    Medical condition: Achondroplasia in Children
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000452 Achondroplasia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 07:29:35 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA